HIV-2 may slow progression of a subsequently acquired HIV-1 infection through cross-neutralizing antibodies and polyfunctional CD8+ T cells. We hypothesized that HIV-1/2 dually infected patients compared with HIV-1-infected patients had more preserved immune maturation subsets and less immune activation of T and B cells.
ART-naive patients with HIV-1 (n = 83) or HIV-1/2 dual (n = 27) infections were included in this cross-sectional study at an HIV clinic in Guinea-Bissau. Peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry according to T-cell maturation and activation, regulatory T-cell fraction, and B-cell maturation and activation.
HIV-1/2 dually infected patients had lower levels of HIV-1 RNA compared with patients with HIV-1 infection, but the levels of total HIV RNA (HIV-1 and HIV-2) were similar in the two patient groups. T-cell maturation, and proportions of regulatory T cells (FoxP3+) were also similar in the two groups. HIV-1/2 dually infected patients had higher proportions of CD4+ and CD8+ T cells positive for the activation marker CD38, but there was no difference in other T-cell activation markers (CD28, CTLA-4, PD-1). HIV-1/2 dually infected patients also had higher proportions of IgM-only B cells and plasmablasts.
HIV-1/2 was not associated with less immune perturbations than for HIV-1 infection.
aBandim Health Project, Indepth Network, Bissau, Guinea-Bissau
bDepartment of Clinical Immunology
cDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
dNational HIV Programme, Ministry of Health, Bissau, Guinea-Bissau
eDepartment of Laboratory Medicine, Lund University, Lund, Sweden
fNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
gGloHAU, Center for Global Health, School of Public Health, Aarhus University, Aarhus
hSection of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, Denmark.
Correspondence to Bo L. Hønge, Department of Clinical Immunology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus, Denmark. Tel: +45 23718870; fax: +45 78455015; e-mail: email@example.com
Received 31 July, 2018
Revised 1 February, 2019
Accepted 5 February, 2019
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).